Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Columbia University Medical Center, New York, New York.
Clin Cancer Res. 2022 Jun 13;28(12):2610-2622. doi: 10.1158/1078-0432.CCR-21-4437.
Clonal malignant T lymphocytes constitute only a fraction of T cells in mycosis fungoides skin tumors and in the leukemic blood of Sézary syndrome, the classic types of cutaneous T-cell lymphomas. However, lack of markers specific for malignant lymphocytes prevents distinguishing them from benign T cells, thus delaying diagnosis and the development of targeted treatments. Here we applied single-cell methods to assess the transcriptional profiles of both malignant T-cell clones and reactive T lymphocytes directly in mycosis fungoides/Sézary syndrome patient samples.
Single-cell RNA sequencing was used to profile the T-cell immune repertoire simultaneously with gene expression in CD3+ lymphocytes from mycosis fungoides and healthy skin biopsies as well as from Sézary syndrome and control blood samples. Transcriptional data were validated in additional advanced-stage mycosis fungoides/Sézary syndrome skin and blood samples by immunofluorescence microscopy.
Several nonoverlapping clonotypes are expanded in the skin and blood of individual advanced-stage mycosis fungoides/Sézary syndrome patient samples, including a dominant malignant clone as well as additional minor malignant and reactive clones. While we detected upregulation of patient-specific as well as mycosis fungoides- and Sézary syndrome-specific oncogenic pathways within individual malignant clones, we also detected upregulation of several common pathways that included genes associated with cancer cell metabolism, cell-cycle regulation, de novo nucleotide biosynthesis, and invasion.
Our analysis unveils new insights into mycosis fungoides/Sézary syndrome pathogenesis by providing an unprecedented report of the transcriptional profile of malignant T-cell clones in the skin and blood of individual patients and offers novel prospective targets for personalized therapy.
克隆性恶性 T 淋巴细胞仅构成蕈样真菌病皮肤肿瘤和 Sézary 综合征白血病血液中 T 细胞的一部分,这是皮肤 T 细胞淋巴瘤的典型类型。然而,缺乏恶性淋巴细胞特异性标志物可防止其与良性 T 细胞区分开来,从而延迟诊断和靶向治疗的发展。在这里,我们应用单细胞方法直接在蕈样真菌病/Sézary 综合征患者样本中评估恶性 T 细胞克隆和反应性 T 淋巴细胞的转录谱。
单细胞 RNA 测序用于同时分析 CD3+淋巴细胞的 T 细胞免疫受体库以及蕈样真菌病和健康皮肤活检以及 Sézary 综合征和对照血液样本中的基因表达。通过免疫荧光显微镜在额外的晚期蕈样真菌病/Sézary 综合征皮肤和血液样本中验证转录数据。
在个别晚期蕈样真菌病/Sézary 综合征患者样本的皮肤和血液中,可扩增多个非重叠的克隆型,包括一个优势恶性克隆以及其他次要恶性和反应性克隆。虽然我们在单个恶性克隆中检测到患者特异性以及蕈样真菌病和 Sézary 综合征特异性致癌途径的上调,但我们还检测到几个常见途径的上调,包括与癌细胞代谢、细胞周期调节、从头核苷酸合成和侵袭相关的基因。
我们的分析通过提供个体患者皮肤和血液中恶性 T 细胞克隆转录谱的前所未有的报告,为蕈样真菌病/Sézary 综合征发病机制提供了新的见解,并为个性化治疗提供了新的潜在靶点。